ACC 2023: Late-Breaking Science Video Collection

Published: 06 March 2023

  • Views:

    Views Icon 5185

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data. 

 

For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series. 

 

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

More from this programme

Part 1

Late-Breaker Discussion Series

Host, Dr Harriette Van Spall is joined by principle investigators for discussion on selected late-breaking trials.  

5 sessions
The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen Watch now
The REVIVED-BCIS2 Viability Study with Dr Harriette Van Spall, Dr Divaka Perera & Dr Peter O'Kane Watch now
The BETTER-CARE HF Trial with Dr Harriette Van Spall & Dr Amrita Mukhopadhyay Watch now
The COORDINATE-Diabetes Trial with Dr Harriette Van Spall, Dr Neha J Pagidipati & Dr Christopher B Granger Watch now
The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti Watch now

Part 2

Expert Interviews

11 sessions
Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial Watch now
RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI Watch now
Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study Watch now
Mini-Thoracotomy Vs Sternoctomy for Degenerative Valve Disease: The UK Mini-Mitral Study Watch now
TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial Watch now
Pulsed Field Ablation in Persistent Atrial Fibrillation Patients: The PULSED AF Trial Watch now
MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients Watch now
Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF Watch now
BMAD Trial: μCor in Ambulatory Decompensated Heart Failure Watch now
The STELLAR Phase II Trial: Sotatercept in Patients With Pulmonary Arterial Hypertension Watch now
Inflammatory Risk from Statin-Treated Patients: Findings from PROMINENT, REDUCE-IT and STRENGTH Watch now

Part 3

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023. 

2 sessions
ACC.23 Late-breaking Science Wrap Up Watch now
What's Hot at ACC.23? Late-breaking Science Preview Watch now

Part 4

Highlights Reviews

4 sessions
Interventional Late-breaking Highlights with Dr Mirvat Alasnag & Dr Khaled Al-Shaibi Watch now
Lipid Management & the CLEAR Trial with Dr Erin Michos Watch now
Obesity Management Strategies in 2023 with Dr Harold Bays Watch now
ACC.23 President Interview with Dr B Hadley Wilson Watch now

Part 5

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

7 sessions
Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers Watch now
Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque Watch now
Drs Day, Lambert & Ackerman: Passion For Cardiovascular Research & Advice for Researchers Watch now
Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers Watch now
Dr Wilson on Why Did He Choose Cardiology & His Advice for Early-career Faculty Watch now
Dr Hahn: Innovative Areas of Cardiovascular Science in 2023 Watch now
Dr Forrest: Structural Heart Innovations and Advice to Young Researchers Watch now

About the episode

We are joined onsite by Dr John Forrest (Yale Valve Clinic, US) in this short video, who outlines the three-year outcomes of the Evolut Low-Risk Trial (Medtronic Cardiovascular). This study aimed to compare transcatheter aortic valve replacement (TAVR) using Medtronic's TAVR valve with surgical aortic valve replacement (SAVR) in over 2000 patients with aortic stenosis who had low surgical risk.

TAVR had consistent benefit at 3 years compared with surgery in terms of all-cause mortality and disabling stroke.

Questions:

  1. What is the reasoning behind this trial?
  2. Please outline the patient population and study design.
  3. What are the main results?
  4. What are the implications of these findings for clinical practice?
  5. What further research is required?

Recorded on-site at ACC.23, New Orleans, 2023. 

Faculty Biographies

John Forrest

View full profile

Comments

You must be to comment. If you are not registered, you can register here.